Tonix strives for pandemic readiness with new US manufacturing facility
The company's goal is to design and test new vaccines for novel pathogens within 100 days of a potential pandemic threat
Vaccines for monkeypox, smallpox and COVID-19 are among some of the products that will be developed by Tonix Pharmaceuticals at its new clinical-scale manufacturing facility in North Dartmouth, Massachusetts.
The clinical-stage biopharma company officially launched its Advanced Development Center (ADC) with a ribbon cutting ceremony on Tuesday. Tonix plans to develop vaccines against infectious diseases at the new facility using its recombinant pox virus platform technology, which it says is ‘rapidly deployable for addressing potential novel or emerging pathogens.’
The 45,000 sq ft facility features single-use bioreactors and purification suites with equipment for GMP production of vaccines for clinical trials, including the capability to produce sterile vaccines in glass bottles. It has been designated a Biosafety Level 2 site, a Centers for Disease Control and Prevention label which means the microbes there pose moderate hazards to laboratorians and the environment.
According to Tonix Pharmaceuticals CEO Seth Lederman, the facility will accelerate development of vaccines targeting infectious diseases.
He commented: ‘The ADC greatly enhances our ability to progress our pipeline of vaccines for infectious diseases, including monkeypox, smallpox and COVID-19. We believe that the recombinant pox virus platform technology underlying our key vaccines in development, TNX-801, TNX-1840 and TNX-1850, coupled with our capabilities at the Tonix R&D Center (RDC) for research and development, will be rapidly deployable for addressing potential novel or emerging pathogens, with simplified distribution and administration, relative to modified mRNA-based vaccines.’
Lederman said the company’s goal is to ‘be able to design and test new recombinant pox virus vaccines against novel pathogens within the 100 days of recognition of a potential emerging pandemic threat’, noting that this timeline meets criteria set out by the White House Office of Science and Technology Policy.
Tonix’s portfolio features a range of investigational new drugs or biologics that are progressing through clinical trials. These include TNX-102 SL, a candidate in mid-Phase 3 development for the management of fibromyalgia, and TNX-102 SL, which is being developed to treat Long COVID.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance